Jaguar health reports statistically significant improvement in breast cancer patients in its phase 3 ontarget trial for its cancer supportive care drug crofelemer

Adult patients with breast cancer are a prespecified subgroup of the recently conducted ontarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea ontarget results in breast cancer patients have been submitted to a relevant oncology conference san francisco, ca / accesswire / october 1, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") today announced that the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the company's phase 3 ontarget trial indicate that crofelemer achieved statistical significance in this subgroup. patients with breast cancer accounted for nearly 180 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by jaguar family company napo pharmaceuticals for diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy.
JAGX Ratings Summary
JAGX Quant Ranking